光诱导和节约氧气的化物纳米囊用于氧化损伤强化瘤治疗
Guobo Chen1, Xiang Wang1, Zongyan He1
1School of Materials and Chemistry, Institute of Bismuth, University of Shanghai for Science and Technology, Shanghai 200093, China.
Molecules (Basel, Switzerland)
|June 10, 2023
概括
这项研究开发了一种光触发纳米放大器 (IrP-T),可以产生反应性氧物种 (ROS),以增强光动力学疗法 (PDT). 这种方法有效地向癌细胞,即使在低氧条件下,通过放大氧化应激来改善瘤损伤.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 癌症治疗 癌症治疗
背景情况:
- 调节细胞氧化还原稳定和诱导氧化应激是癌症治疗的关键策略.
- 有机纳米材料具有潜力,但在这种治疗方法中未得到充分利用.
研究的目的:
- 开发一种光触发反应性氧物种 (ROS) 破坏性纳米放大器 (IrP-T) 用于增强光动力学疗法 (PDT).
- 研究ROS生成和MTH1抑制在癌症治疗中的协同效应.
主要方法:
- 使用两性复合物和MTH1抑制剂 (TH287) 制造IrP-T.
- 利用绿光刺激触发ROS生成和氧化损伤.
- 评估8-oxo-dGTP的积累以量化氧化应激.
主要成果:
- 在光刺激下,IrP-T有效催化氧,产生ROS,诱导氧化损伤.
- TH287显著增加了8-oxo-dGTP的积累,放大了氧化应激,促进了细胞死亡.
- 通过最大限度地利用氧气,IrP-T证明了增强的PDT疗效,特别是在缺氧瘤中.
结论:
- 开发的IrP-T纳米放大器为氧化损伤和协同PDT提供了一个新的治疗策略.
- 这种方法有望改善癌症治疗,特别是在挑战低氧瘤微环境时.
- 纳米囊结构为增强基于氧化应激的癌症治疗提供了一个有价值的平台.
相关概念视频
Electron Transport Chain: Complex I and II
14.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.6K
Cancer Therapies
7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


